Drug intelligence / Profile preview

iruxol

Development stage: Unknown
Lead developer: Abbott
Modality: Small Molecules, Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes
Administration: Topical

Overview

Iruxol is a topical combination drug used primarily for the enzymatic debridement of necrotic tissue in wounds, burns, and chronic ulcers. It contains two active ingredients: collagenase (specifically clostridiopeptidase A derived from Clostridium histolyticum) and chloramphenicol. Collagenase acts by breaking down collagen in necrotic tissue, facilitating its removal and promoting wound healing. Chloramphenicol is a broad-spectrum antibiotic that helps prevent or treat local infection at the wound site[1][2][4]. The ointment formulation is applied directly to affected skin areas to aid in cleaning wounds and supporting tissue regeneration.

Brand names: Iruxol

Targets

Neuraminidase

Beyond the preview

Go deeper on iruxol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on iruxol.

Explore the full profile